Bookmark and Share
BioAssay: AID 624397

Late stage assay provider counterscreen for activators of Aryl hydrocarbon receptor (AHR): Absorbance-based cell-based assay to identify compounds that modulate proliferation of ER-positive breast cancer cells (MCF7), Set 2

Name: Late stage assay provider counterscreen for activators of Aryl hydrocarbon receptor (AHR): Absorbance-based cell-based assay to identify compounds that modulate proliferation of ER-positive breast cancer cells (MCF7), Set 2. ..more
_
   
 Tested Compounds
 Tested Compounds
All(3)
 
 
Active(3)
 
 
 Tested Substances
 Tested Substances
All(3)
 
 
Active(3)
 
 
 Related BioAssays
 Related BioAssays
AID: 624397
Data Source: The Scripps Research Institute Molecular Screening Center (MCF7_GROWTH_INH_ABS_0096_1X%INH MCSRUN)
BioAssay Type: Confirmatory, Concentration-Response Relationship Observed
Depositor Category: NIH Molecular Libraries Probe Production Network, Assay Provider
Deposit Date: 2012-07-20
Hold-until Date: 2013-07-19
Modify Date: 2013-07-19

Data Table ( Complete ):           View Active Data    View All Data
BioActive Compounds: 3
Related Experiments
Show more
AIDNameTypeComment
2796Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)Screeningdepositor-specified cross reference: Primary screen (AHR activators in singlicate)
2804Summary of probe development efforts to identify activators of the Aryl Hydrocarbon Receptor (AHR)Summarydepositor-specified cross reference: Summary (AHR activators)
2845Luminescence-based cell-based high throughput confirmation assay for activators of the Aryl Hydrocarbon Receptor (AHR)Screeningdepositor-specified cross reference: Confirmation (AHR activators in triplicate)
434939Counterscreen for activators of the Aryl Hydrocarbon Receptor (AHR): luminescence-based cell-based high throughput screening assay to identify activators of the Pregnane X Receptor (PXR)Screeningdepositor-specified cross reference: Counterscreen (PXR activators in triplicate)
463086Luminescence-based counterscreen for activators of the Aryl Hydrocarbon Receptor (AHR): cell-based high throughput dose response screening assay for activators of the Pregnane X Receptor (PXR)Confirmatorydepositor-specified cross reference: Dose response counterscreen (PXR activators in triplicate)
463088Luminescence-based cell-based high throughput dose response assay for activators of the Aryl Hydrocarbon Receptor (AHR)Confirmatorydepositor-specified cross reference: Dose response (AHR activators in triplicate)
493060Late stage results for the probe development effort to identify activators of the Aryl Hydrocarbon Receptor (AHR): Luminescence-based cell-based dose response assay for AHR activatorsConfirmatorydepositor-specified cross reference: Dose response primary screen (Ahr activators in triplicate)
493061Late stage counterscreen results for the probe development effort to identify activators of the Aryl Hydrocarbon Receptor (AHR): Luminescence-based cell-based dose response assay for activators of the Pregnane X Receptor (PXR)Confirmatorydepositor-specified cross reference: Dose response counterscreen (Ahr activators in triplicate)
602169Late stage assay provider counterscreen for the probe development effort to identify activators of the Aryl Hydrocarbon Receptor (AHR): Luminescence-based Human Ovarian Carcinoma (BG1Luc4E2) Cell-based assay to identify inhibitors of Estrogen Receptor-Dependent Gene ExpressionOtherdepositor-specified cross reference: Counterscreen (Estrogen-Dependent reporter in triplicate)
602171Late stage assay provider counterscreen for the probe development effort to identify activators of the Aryl Hydrocarbon Receptor (AHR): Luminescence-based Human Hepatoma (HG2L7.5c1) Cell-based assay to identify activators of AhROtherdepositor-specified cross reference: Primary screen (Ahr activators in triplicate)
602172Late stage assay provider counterscreen for activators of Aryl hydrocarbon receptor (AHR): Radiometric electrophoretic mobility shift assay (EMSA) to identify compounds that enhance formation of AHR:DRE (dioxin response element) complexes in vitroConfirmatorydepositor-specified cross reference: Counterscreen (EMSA in triplicate)
602173Late stage assay provider counterscreen for activators of Aryl hydrocarbon receptor (AHR): Absorbance-based cell-based assay to identify compounds that modulate proliferation of ER-negative liver cancer cells (HEPG2)Otherdepositor-specified cross reference: Counterscreen (HepG2 proliferation in triplicate)
602174Late stage assay provider counterscreen for activators of Aryl hydrocarbon receptor (AHR): Absorbance-based cell-based assay to identify compounds that modulate proliferation of ER-positive breast cancer cells (MCF7)Otherdepositor-specified cross reference: Counterscreen (MCF7 proliferation in triplicate)
602226Late stage assay provider counterscreen for activators of Aryl hydrocarbon receptor (AHR): Radiometric [3H]TCDD Competitive Binding assay to identify compounds that inhibit binding of radiolabeled TCDD to AHR in cytosol isolated from guinea pig liverOthersame project related to Summary assay
624398Late stage assay provider counterscreen for the probe development effort to identify activators of the Aryl Hydrocarbon Receptor (AHR): Luminescence-based Human Ovarian Carcinoma (BG1Luc4E2) Cell-based assay to identify inhibitors of Estrogen Receptor-Dependent Gene Expression, Set 2Othersame project related to Summary assay
624399Late stage assay provider counterscreen for the probe development effort to identify activators of the Aryl Hydrocarbon Receptor (AHR): Luminescence-based Human Ovarian Carcinoma (BG1Luc4E2) Cell-based assay to identify activators of Estrogen Receptor-Dependent Gene ExpressionOthersame project related to Summary assay
624400Late stage assay provider counterscreen for activators of Aryl hydrocarbon receptor (AHR): Radiometric [3H]TCDD Competitive Binding assay to identify compounds that inhibit binding of radiolabeled TCDD to AHR in cytosol isolated from guinea pig liver, Set 2Othersame project related to Summary assay
624401Late stage assay provider counterscreen for the probe development effort to identify activators of the Aryl Hydrocarbon Receptor (AHR): Luminescence-based Human Hepatoma (HG2L7.5c1) Cell-based assay to identify activators of AhR, Set 2Confirmatorysame project related to Summary assay
624402Late stage assay provider dose-response counterscreen for activators of Aryl hydrocarbon receptor (AhR): Radiometric electrophoretic mobility shift assay (EMSA) to identify compounds that stimulate AhR transformation and binding to its specific DNA recognition site in vitroOthersame project related to Summary assay
Description:
Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)
Center Affiliation: The Scripps Research Institute (TSRI)
Assay Provider: Michael Denison, University of California, Davis
Network: Molecular Libraries Probe Production Centers Network (MLPCN)
Grant Proposal Number: 1-X01-DA026558-01
Grant Proposal PI: Michael Denison
External Assay ID: MCF7_GROWTH_INH_ABS_0096_1X%INH MCSRUN

Name: Late stage assay provider counterscreen for activators of Aryl hydrocarbon receptor (AHR): Absorbance-based cell-based assay to identify compounds that modulate proliferation of ER-positive breast cancer cells (MCF7), Set 2.

Description:

Transcription factors are critical regulators of gene expression (1). Under conditions such as environmental stress and exposure to endogenous toxins, transcription factors can rapidly modulate the transcription of genes whose products regulate cell proliferation and metabolism. The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor of the basic helix-loop-helix protein superfamily involved in the biological response to aromatic hydrocarbons, and regulates the expression of xenobiotic-metabolizing enzymes such as cytochrome P450, aldehyde dehydrogenase, quinone reductase, and other phase I and phase II detoxification genes (2, 3). In response to various compounds, including the environmental pollutants dioxins, benzo(a)pyrene, dietary contaminants, grapefruit juice, endogenous toxins, and plant products such as carotinoids, nicotine and caffeine (2, 4-6), cytosolic AHR complexes with chaperones hsp90, p23, and XAP2, translocates to the nucleus where it dimerizes with the AHR nuclear translocator (ARNT) to influence target gene transcription (7, 8). Gain-of-function studies in mice reveal the oncogenic potential of AHR (9), while other reports show roles for AHR in diverse biologic events such as organ development (10, 11), immune function and allergy (12), and estrogen responsiveness (13). The identification of agonists of AHR will provide useful tools to elucidate the roles of this receptor in cell metabolism, transcriptional control, and tumor formation (14-16).

References:

1. Ptashne, M., Regulation of transcription: from lambda to eukaryotes. Trends Biochem Sci, 2005. 30(6): p. 275-9.
2. McMillan, B.J. and Bradfield, C.A., The aryl hydrocarbon receptor sans xenobiotics: endogenous function in genetic model systems. Mol Pharmacol, 2007. 72(3): p. 487-98.
3. Puga, A., Tomlinson, C.R., and Xia, Y., Ah receptor signals cross-talk with multiple developmental pathways. Biochem Pharmacol, 2005. 69(2): p. 199-207.
4. Bock, K.W. and Kohle, C., Ah receptor: dioxin-mediated toxic responses as hints to deregulated physiologic functions. Biochem Pharmacol, 2006. 72(4): p. 393-404.
5. Denison, M.S. and Nagy, S.R., Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu Rev Pharmacol Toxicol, 2003. 43: p. 309-34.
6. de Waard, P.W., Peijnenburg, A.A., Baykus, H., Aarts, J.M., Hoogenboom, R.L., van Schooten, F.J., and de Kok, T.M., A human intervention study with foods containing natural Ah-receptor agonists does not significantly show AhR-mediated effects as measured in blood cells and urine. Chem Biol Interact, 2008.
7. Hankinson, O., The aryl hydrocarbon receptor complex. Annu Rev Pharmacol Toxicol, 1995. 35: p. 307-40.
8. Petrulis, J.R. and Perdew, G.H., The role of chaperone proteins in the aryl hydrocarbon receptor core complex. Chem Biol Interact, 2002. 141(1-2): p. 25-40.
9. Andersson, P., McGuire, J., Rubio, C., Gradin, K., Whitelaw, M.L., Pettersson, S., Hanberg, A., and Poellinger, L., A constitutively active dioxin/aryl hydrocarbon receptor induces stomach tumors. Proc Natl Acad Sci U S A, 2002. 99(15): p. 9990-5.
10. Ramos, K.S., Transcriptional profiling and functional genomics reveal a role for AHR transcription factor in nephrogenesis. Ann N Y Acad Sci, 2006. 1076: p. 728-35.
11. Walisser, J.A., Glover, E., Pande, K., Liss, A.L., and Bradfield, C.A., Aryl hydrocarbon receptor-dependent liver development and hepatotoxicity are mediated by different cell types. Proc Natl Acad Sci U S A, 2005. 102(49): p. 17858-63.
12. Lawrence, B.P., Denison, M.S., Novak, H., Vorderstrasse, B.A., Harrer, N., Neruda, W., Reichel, C., and Woisetschlager, M., Activation of the aryl hydrocarbon receptor is essential for mediating the anti-inflammatory effects of a novel low-molecular-weight compound. Blood, 2008. 112(4): p. 1158-65.
13. Ohtake, F., Takeyama, K., Matsumoto, T., Kitagawa, H., Yamamoto, Y., Nohara, K., Tohyama, C., Krust, A., Mimura, J., Chambon, P., Yanagisawa, J., Fujii-Kuriyama, Y., and Kato, S., Modulation of oestrogen receptor signalling by association with the activated dioxin receptor. Nature, 2003. 423(6939): p. 545-50.
14. Zhao, B., Baston, D.S., Hammock, B., and Denison, M.S., Interaction of diuron and related substituted phenylureas with the Ah receptor pathway. J Biochem Mol Toxicol, 2006. 20(3): p. 103-13.
15. Garrison, P.M., Tullis, K., Aarts, J.M., Brouwer, A., Giesy, J.P., and Denison, M.S., Species-specific recombinant cell lines as bioassay systems for the detection of 2,3,7,8-tetrachlorodibenzo-p-dioxin-like chemicals. Fundam Appl Toxicol, 1996. 30(2): p. 194-203.
16. Han, D., Nagy, S.R., and Denison, M.S., Comparison of recombinant cell bioassays for the detection of Ah receptor agonists. Biofactors, 2004. 20(1): p. 11-22.
17. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J.T., Bokesch, H., Kenney, S. and Boyd, M.R. (1990) New colorimetric cytotoxicity assay for anticancer-drug screening, J Natl Cancer Inst 82, 1107-1112.
18. Vichai, V. and Kirtikara, K. (2006) Sulforhodamine B colorimetric assay for cytotoxicity screening, Nat Protocol 1, 1112-1116.
19. Papazisis, K.T., Geromichalos, G.D., Dimitriadis, K.A. and Kortsaris, A.H. (1997) Optimization of the sulforhodamine B colorimetric assay, J Immunol Meth 208, 151-158.

Keywords:

late stage, powders, purchased, synthesized, AHR, aryl hydrocarbon receptor, receptor, transcription factor, triplicate, dose response, counterscreen, assay provider, cell, liver, proliferation, viability, growth, MCF7, breast, sulforhodamine B, activator, agonist, activation, Scripps, Scripps Florida, The Scripps Research Institute Molecular Screening Center, SRIMSC, Molecular Libraries Probe Production Centers Network, MLPCN.
Protocol
Assay Overview:
The purpose of this assay is to determine the ability of test compounds to inhibit estrogen-dependent and/or -independent cell proliferation of human breast (T47D), ovarian (BG1) and liver (HepG2) cells in an AHR-dependent manner in vitro. Estrogen-responsive cells (T47D and BG1) are preincubated in 96-well culture plates with phenol red-free media containing charcoal-stripped serum for 5 days (to reduce endogenous estrogen levels) before use. Cells in 96-well culture plates grown in the presence (T47D and BG1) and absence (HepG2) of estradiol 17b and in the absence or presence of test compound for 7 - 10 days (TCDD is used as a positive control). Media is removed, the cells fixed and total cell biomass stained with sulforhodamine B, washed and absorbance at 490 nm determined. This assay provides a measure of total cell numbers over a wide range of cell numbers (33). Since proliferation of cancer cell growth can be regulated by multiple mechanisms (both hormone-dependent and independent) the assays here are designed to identify those AHR agonists that will also inhibit estrogen-dependent and -independent proliferation of these cancer cell lines, with the extent of inhibition directly related to the level of AHR activation. Comparison of the inhibition of proliferation by test compounds of T47D and BG1 cells grown in the absence or presence of estrogen will allow specific determination of AHR-dependent inhibition of proliferation that is estrogen-/estrogen receptor-dependent. Determination of the inhibition of proliferation of estrogen receptor-deficient HepG2 cells and of T47D and BG1 cells grown in the absence of estrogen, will allow specific determination of AHR-dependent inhibition of proliferation that is estrogen-/estrogen receptor-independent. Thus, multiple mechanisms of inhibition of cell proliferation will be assessed. Details of this assay protocol can be found in (Skehan et al., 1990; Vichai and Kirtikara, 2006; Papazisis et al., 1997) (17-19). Compounds were tested using a dose response series up to a maximum nominal concentration of 10 uM.
Protocol Summary:
1. Cells were harvested at 90% confluent by addition of 2 ml trypsin, counted and plated in 24-wells plates at 2,000 cells/well in a-MEM media containing 10% fetal bovine serum. For these studies, ER-positive (human breast cancer (MCF7)) and ER-negative (human hepatoma (HepG2)) cells were examined.
2. The plates were incubated at 37 C for 24 hour.
3. After 24 hours, the medium was changed and cells were treated with DMSO (1 ul/ml), TCDD (10 nM) or 10 uM of the test compounds and incubated for 8-10 days at 37 C. For concentration response analysis a range of 10 nM to 10 uM of the test compounds were used. The effect of all chemicals (at all concentrations) were examined in at least triplicate incubations. During the incubation period, medium was changed and cells were re-dosed with chemical every 48 hours.
4. Following removal of media by aspiration, 250 ml of 10% cold (4 C) TCA were gently added to the wells.
5. Plates were incubated for 30 min at 4 C, then washed 5 times with deionized water and left to dry at room temperature for at least 1 hour.
6. Cells were stained by the addition and incubation (20 min) with 250 ml of SRB dissolved in 1% acetic acid.
7. Unbound dye was removed by washing with 1% acetic acid five times.
8. Bound dye was solubilized with 150 ml of unbuffered Tris base (10 mM, pH 10.5) for 10 min on a shaker.
9. Finally, an aliquot (130 ml) of the Tris buffer containing SRB dye was transferred to a 96-well plate. The total absorbance at 490 nm was determined, and specific absorbance determined after subtraction of background absorbance (i.e., absorbance at 650 nm). Results are presented as a percent of proliferation (absorbance) of cells exposed to DMSO, with negative values representing inhibition and positive values representing enhancement of proliferation.
IC50 values from sigmoidal concentration-response curves were determined using the four-parameter Hill equation (SigmaPlot (Systat)). The compounds exhibited an estimated IC50 of 3 uM, but the dose response curve was steep, so the value is approximate.
PubChem Activity Outcome and Score:
Compounds that inhibit proliferation by less than 20% were considered inactive. Compounds that inhibit proliferation equal to or greater than 20% were considered active.
The reported PubChem Activity Score has been normalized to 100% observed max % inhibition. Negative max % inhibition values are reported as activity score zero.
The PubChem Activity Score range for active compounds is 100-96. There are no inactive compounds.
Comment
This assay was run by the assay provider. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the plate, compounds that modulate cell growth and/or well absorbance. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided.
Categorized Comment - additional comments and annotations
From PubChem:
Assay Format: Cell-based
Assay Cell Type: MCF-7
Result Definitions
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
ScoreThe BioAssay activity ranking scoreInteger
1Max Inhibition at 10 uM (10μM**)The maximum % of the cell proliferation in the presence of 10 micromolar compound. Values shown are normalized to cells treated with DMSO.Float%
2Qualifier [IC50]Activity Qualifier identifies if the resultant data IC50 came from a fitted curve or was determined manually to be less than or greater than its listed IC50 concentration. ~ symbol indicates approximate value.String
3IC50*The concentration at which 50 percent of the activity in the compound assay is observed; (IC50) shown in micromolar.FloatμM

* Activity Concentration. ** Test Concentration.
Additional Information
Grant Number: 1-X01-DA026558-01

Data Table (Concise)
Data Table ( Complete ):     View Active Data    View All Data
PageFrom: